Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BSTG NYSE:ELMD NYSE:NVRO NASDAQ:NYXH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/AELMDElectromed$20.51+2.4%$20.98$13.74▼$35.56$172.00M0.4180,704 shs70,094 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81801,886 shs753,602 shsNYXHNyxoah$7.75-2.9%$7.35$5.55▼$11.87$271.80M1.6275,943 shs52,398 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTGBiostage0.00%0.00%0.00%0.00%0.00%ELMDElectromed-0.50%-8.17%-4.44%-14.92%+34.91%NVRONevro0.00%0.00%0.00%0.00%-30.16%NYXHNyxoah+1.53%+5.70%+4.04%+27.88%-5.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTGBiostageN/AN/AN/AN/AN/AN/AN/AN/AELMDElectromed1.5061 of 5 stars2.05.00.00.00.61.70.6NVRONevro0.1777 of 5 stars1.00.00.00.00.01.70.6NYXHNyxoahN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTGBiostage 0.00N/AN/AN/AELMDElectromed 4.00Strong Buy$38.0085.28% UpsideNVRONevro 1.92Reduce$5.36-8.29% DownsideNYXHNyxoah 3.00Buy$14.5087.10% UpsideCurrent Analyst Ratings BreakdownLatest BSTG, NVRO, NYXH, and ELMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTGBiostageN/AN/AN/AN/A($0.26) per shareN/AELMDElectromed$61.44M2.80$0.50 per share41.36$5.10 per share4.02NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72NYXHNyxoah$4.89M53.98N/AN/A$3.60 per share2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTGBiostage-$6.07M-$0.58N/A∞N/AN/AN/A-174.43%N/AELMDElectromed$5.15M$0.7927.35∞N/A11.34%15.71%13.37%N/ANVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)NYXHNyxoah-$64.10M-$2.130.00N/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)Latest BSTG, NVRO, NYXH, and ELMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025NYXHNyxoah-$0.60N/AN/AN/A$1.33 millionN/A5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTGBiostageN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTGBiostageN/A2.732.73ELMDElectromedN/A5.104.74NVRONevro0.675.023.76NYXHNyxoah0.223.593.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTGBiostageN/AELMDElectromed40.82%NVRONevro95.52%NYXHNyxoahN/AInsider OwnershipCompanyInsider OwnershipBSTGBiostage15.30%ELMDElectromed14.00%NVRONevro3.20%NYXHNyxoah17.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSTGBiostage713.88 million11.76 millionNot OptionableELMDElectromed1608.39 million7.36 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableBSTG, NVRO, NYXH, and ELMD HeadlinesRecent News About These CompaniesNyxoah SA (NYXH) Latest Stock News & Headlines - Yahoo FinanceJune 27, 2025 | finance.yahoo.comNyxoah S.A. (NASDAQ:NYXH) Sees Large Increase in Short InterestJune 16, 2025 | marketbeat.comInvitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025June 13, 2025 | globenewswire.comBrokers Set Expectations for Nyxoah FY2026 EarningsJune 10, 2025 | marketbeat.comNyxoah to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comKepler Capital Reaffirms Their Buy Rating on Nyxoah (NYXH)May 24, 2025 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 18, 2025 | gurufocus.comNyxoah outlines U.S. Genio launch plan with 50-member team as FDA approval expected Q2 2025May 16, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 16, 2025 | accessnewswire.comANyxoah S.A. (NASDAQ:NYXH) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comNyxoah SA (NYXH) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesMay 15, 2025 | finance.yahoo.comNyxoah SA (NYXH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 14, 2025 | accessnewswire.comANyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue EstimatesMay 14, 2025 | zacks.comNyxoah Reports First Quarter Financial and Operating ResultsMay 14, 2025 | globenewswire.com1NYXH : Examining the Future: Nyxoah's Earnings OutlookMay 13, 2025 | benzinga.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXHMay 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 12, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 10, 2025 | accessnewswire.comAPublication relating to transparency notificationsMay 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBSTG, NVRO, NYXH, and ELMD Company DescriptionsBiostage OTCMKTS:BSTG$4.45 0.00 (0.00%) As of 07/24/2023Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.Electromed NYSE:ELMD$20.51 +0.49 (+2.45%) Closing price 04:00 PM EasternExtended Trading$20.50 -0.01 (-0.05%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Nyxoah NASDAQ:NYXH$7.75 -0.23 (-2.88%) As of 04:00 PM EasternNyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
